Everolimus as second-line therapy for metastatic renal cell carcinoma: A 'real-life' study

Mimma Rizzo, Gaetano Facchini, Clementina Savastano, Giuseppe Di Lorenzo, Luigi De Lucia, Luigi Maiorino, Beniamino Casale, Giuseppe Grimaldi, Roberta Formato, Antonio Febbraro, Giacomo Cartenì

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aims: This study, conducted in a 'field-practice' scenario, investigates the effectiveness and safety of everolimus in the second-line treatment of metastatic renal cell carcinoma (mRCC) patients. Patients & methods: mRCC patients, who started everolimus 10 mg/day after failure of first-line VEGF receptor-targeted tyrosine kinase inhibitor, were included in this study. Study end points were treatment response, progression-free survival and tolerability. Results: In total, 100 patients were assessed; the median duration of everolimus treatment was 7.1 months (95% CI: 5.7-8.5). A total of 19% of patients experienced a partial response and 62% of patients reached a stable disease. Median progression-free survival was 8 months (95% CI: 6.7-9.3). A total of 75% of patients experienced adverse events; no grade 4 adverse events were reported. Conclusion: These findings, obtained in a 'field-practice' scenario, support the use of everolimus for mRCC patients who failed one VEGF receptor-targeted tyrosine kinase inhibitor.

Original languageEnglish
Pages (from-to)219-224
Number of pages6
JournalFuture Oncology
Volume11
Issue number2
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor Receptor
Therapeutics
Protein-Tyrosine Kinases
Disease-Free Survival
Everolimus
Safety

Keywords

  • everolimus
  • mRCC
  • observational studies
  • second-line therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Rizzo, M., Facchini, G., Savastano, C., Lorenzo, G. D., Lucia, L. D., Maiorino, L., ... Cartenì, G. (2015). Everolimus as second-line therapy for metastatic renal cell carcinoma: A 'real-life' study. Future Oncology, 11(2), 219-224. https://doi.org/10.2217/fon.14.170

Everolimus as second-line therapy for metastatic renal cell carcinoma : A 'real-life' study. / Rizzo, Mimma; Facchini, Gaetano; Savastano, Clementina; Lorenzo, Giuseppe Di; Lucia, Luigi De; Maiorino, Luigi; Casale, Beniamino; Grimaldi, Giuseppe; Formato, Roberta; Febbraro, Antonio; Cartenì, Giacomo.

In: Future Oncology, Vol. 11, No. 2, 01.01.2015, p. 219-224.

Research output: Contribution to journalArticle

Rizzo, M, Facchini, G, Savastano, C, Lorenzo, GD, Lucia, LD, Maiorino, L, Casale, B, Grimaldi, G, Formato, R, Febbraro, A & Cartenì, G 2015, 'Everolimus as second-line therapy for metastatic renal cell carcinoma: A 'real-life' study', Future Oncology, vol. 11, no. 2, pp. 219-224. https://doi.org/10.2217/fon.14.170
Rizzo, Mimma ; Facchini, Gaetano ; Savastano, Clementina ; Lorenzo, Giuseppe Di ; Lucia, Luigi De ; Maiorino, Luigi ; Casale, Beniamino ; Grimaldi, Giuseppe ; Formato, Roberta ; Febbraro, Antonio ; Cartenì, Giacomo. / Everolimus as second-line therapy for metastatic renal cell carcinoma : A 'real-life' study. In: Future Oncology. 2015 ; Vol. 11, No. 2. pp. 219-224.
@article{97c760b5ea164ac79aa2400ab62521a0,
title = "Everolimus as second-line therapy for metastatic renal cell carcinoma: A 'real-life' study",
abstract = "Aims: This study, conducted in a 'field-practice' scenario, investigates the effectiveness and safety of everolimus in the second-line treatment of metastatic renal cell carcinoma (mRCC) patients. Patients & methods: mRCC patients, who started everolimus 10 mg/day after failure of first-line VEGF receptor-targeted tyrosine kinase inhibitor, were included in this study. Study end points were treatment response, progression-free survival and tolerability. Results: In total, 100 patients were assessed; the median duration of everolimus treatment was 7.1 months (95{\%} CI: 5.7-8.5). A total of 19{\%} of patients experienced a partial response and 62{\%} of patients reached a stable disease. Median progression-free survival was 8 months (95{\%} CI: 6.7-9.3). A total of 75{\%} of patients experienced adverse events; no grade 4 adverse events were reported. Conclusion: These findings, obtained in a 'field-practice' scenario, support the use of everolimus for mRCC patients who failed one VEGF receptor-targeted tyrosine kinase inhibitor.",
keywords = "everolimus, mRCC, observational studies, second-line therapy",
author = "Mimma Rizzo and Gaetano Facchini and Clementina Savastano and Lorenzo, {Giuseppe Di} and Lucia, {Luigi De} and Luigi Maiorino and Beniamino Casale and Giuseppe Grimaldi and Roberta Formato and Antonio Febbraro and Giacomo Carten{\`i}",
year = "2015",
month = "1",
day = "1",
doi = "10.2217/fon.14.170",
language = "English",
volume = "11",
pages = "219--224",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Everolimus as second-line therapy for metastatic renal cell carcinoma

T2 - A 'real-life' study

AU - Rizzo, Mimma

AU - Facchini, Gaetano

AU - Savastano, Clementina

AU - Lorenzo, Giuseppe Di

AU - Lucia, Luigi De

AU - Maiorino, Luigi

AU - Casale, Beniamino

AU - Grimaldi, Giuseppe

AU - Formato, Roberta

AU - Febbraro, Antonio

AU - Cartenì, Giacomo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Aims: This study, conducted in a 'field-practice' scenario, investigates the effectiveness and safety of everolimus in the second-line treatment of metastatic renal cell carcinoma (mRCC) patients. Patients & methods: mRCC patients, who started everolimus 10 mg/day after failure of first-line VEGF receptor-targeted tyrosine kinase inhibitor, were included in this study. Study end points were treatment response, progression-free survival and tolerability. Results: In total, 100 patients were assessed; the median duration of everolimus treatment was 7.1 months (95% CI: 5.7-8.5). A total of 19% of patients experienced a partial response and 62% of patients reached a stable disease. Median progression-free survival was 8 months (95% CI: 6.7-9.3). A total of 75% of patients experienced adverse events; no grade 4 adverse events were reported. Conclusion: These findings, obtained in a 'field-practice' scenario, support the use of everolimus for mRCC patients who failed one VEGF receptor-targeted tyrosine kinase inhibitor.

AB - Aims: This study, conducted in a 'field-practice' scenario, investigates the effectiveness and safety of everolimus in the second-line treatment of metastatic renal cell carcinoma (mRCC) patients. Patients & methods: mRCC patients, who started everolimus 10 mg/day after failure of first-line VEGF receptor-targeted tyrosine kinase inhibitor, were included in this study. Study end points were treatment response, progression-free survival and tolerability. Results: In total, 100 patients were assessed; the median duration of everolimus treatment was 7.1 months (95% CI: 5.7-8.5). A total of 19% of patients experienced a partial response and 62% of patients reached a stable disease. Median progression-free survival was 8 months (95% CI: 6.7-9.3). A total of 75% of patients experienced adverse events; no grade 4 adverse events were reported. Conclusion: These findings, obtained in a 'field-practice' scenario, support the use of everolimus for mRCC patients who failed one VEGF receptor-targeted tyrosine kinase inhibitor.

KW - everolimus

KW - mRCC

KW - observational studies

KW - second-line therapy

UR - http://www.scopus.com/inward/record.url?scp=84921373590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921373590&partnerID=8YFLogxK

U2 - 10.2217/fon.14.170

DO - 10.2217/fon.14.170

M3 - Article

C2 - 25078333

AN - SCOPUS:84921373590

VL - 11

SP - 219

EP - 224

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 2

ER -